Akebia Therapeutics, Inc. (NASDAQ:AKBA) Receives Consensus Rating of "Moderate Buy" from Analysts
Shares of Akebia Therapeutics, Inc. (NASDAQ:AKBA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight research firms that are presently covering the company...
MarketBeat·12h ago
More News
Q32 Bio Stock Soars On Selling Experimental Drug To Akeba For Up To $592M
The company said that the sale extends its cash runway into the second half of 2027.
Stocktwits·10d ago
Q32 Bio Sells Complement Inhibitor ADX-097
Q32 Bio Sells Complement Inhibitor ADX-097 Q32 Bio Sells Complement Inhibitor ADX-097 PR Newswire WALTHAM, Mass., Dec. 1, 2025 -- Asset sale further enables Company's strategic focus on advancing...
PR Newswire·10d ago
Akebia Therapeutics (NASDAQ:AKBA) Downgraded by Wall Street Zen to "Buy"
Wall Street Zen lowered Akebia Therapeutics from a "strong-buy" rating to a "buy" rating in a research note on Friday...
MarketBeat·13d ago
Q2 Earnings Forecast for AKBA Issued By HC Wainwright
Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) - Equities researchers at HC Wainwright issued their Q2 2026 EPS estimates for shares of Akebia Therapeutics in a research note issued to...
MarketBeat·27d ago
Implied Volatility Surging for Akebia Therapeutics Stock Options
Investors need to pay close attention to AKBA stock based on the movements in the options market lately.
Zacks·28d ago
Analysts Offer Predictions for AKBA Q1 Earnings
Akebia Therapeutics, Inc. (NASDAQ:AKBA - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2026 earnings estimates for shares of Akebia Therapeutics in a research note issued...
MarketBeat·28d ago
Theravance's Q3 Earnings Surpass Estimates, Revenues Match
TBPH delivers a third-quarter profit, beating estimates, and 19% revenue growth, fueled by rising collaboration income from Viatris related to Yupelri sales.
Zacks·1mo ago
Akebia Therapeutics (AKBA) Loses 39.9% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
The heavy selling pressure might have exhausted for Akebia Therapeutics (AKBA) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
Zacks·1mo ago
Mettler-Toledo Q3 Earnings Top Estimates, Sales Decline Y/Y
MTD posted stronger-than-expected Q3 results, lifted by segment growth and solid guidance for 2025 and 2026.